Services
testing neo-angiogenic potential
Angiogenesis, the formation of new blood vessels, is a physiological process that plays an essential role in several pathological disorders such as tumor growth, psoriasis or macular degeneration. On the other hand, neo-angiogenesis is involved in tissue regeneration. Therefore, the search for novel drugs that inhibit or stimulate neo-angiogenesis and counteract this imbalance in blood vessel formation resulting in severe diseases is of ever-increasing importance. Evercyte has established relevant and standardizable in vitro model systems that can mimic neo-angiogenesis in vivo and will drive the search for novel drugs.
General information
In vitro model: Evercyte has generated telomerized human umbilical vein endothelial cells (HUVEC/TERT2) that can be grown without limitation while maintaining a primary-like phenotype.
Testing neo-angiogenic potential of compounds
sprout formation from endothelial spheroids
When human umbilical vein endothelial cells (HUVEC/TERT2) are grown in hanging drops, they form 3D spheroids that can be embedded into a collagen matrix. Treatment of these spheroids with vascular endothelial growth factor (VEGF) induces the formation of sprouts. Concommitant cultivation in the presence of VEGF and Cyclosporin A (CSA) significantly reduces sprout formation in a concentration-dependent manner.
Testing endothelial cell proliferation
2D proliferation assay
Telomerized human endothelial cells (HUVEC/TERT2) are seeded into multi-well plates followed by treatment with vascular endothelial growth factor (VEGF) with / without anti-angiogenic agents ranibizumab (Lucentis®) and bevacizumab (Avastin®). Measurement of cellular proliferation demonstrates that Lucentis and Avastin inhibit VEGF induced proliferation in a concentration dependent manner.
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.
